ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
GSK has agreed to buy the vaccine developer Affinivax for $2.1 billion, plus up to $1.2 billion in milestone payments. Affinivax, based in Cambridge, Massachusetts, uses its Multiple Antigen Presenting System in vaccines to induce a protective immune response that’s broader than that of conventional conjugate vaccines. The company’s lead vaccine, AFX3772, targets Streptococcus pneumoniae, a bacterium that can cause infections like pneumonia and meningitis. Affinivax expects it to enter Phase 3 trials this year. In a press release, GSK chief scientific officer Hal Barron says the deal will give the firm access to a “new, potentially disruptive technology.”
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X